Expertise in
5
conditions

Cecile Guillemet

Rouen, FR 
Expertise in
5
conditions
Rouen, FR 

Overview

Cecile Guillemet practices practicing medicine in Rouen, France.

Ms. Guillemet is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Adult Soft Tissue Sarcoma, Fibromatosis, Desmoid Tumor, Alveolar Soft Part Sarcoma, and Tissue Biopsy.

She is actively involved in clinical research, co-authoring 48 peer reviewed articles and participating in 8 clinical trials.

Gender

Female

Locations

Rouen, France
Other Locations
Hôpital Cochin Port Royal
Vandoeuvre-les-nancy, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Use of Cognitive Stimulation Software for Patients Over the Age of 70 Followed for Breast Cancer: COG-TAB-AGE Feasibility Study
Use of Cognitive Stimulation Software for Patients Over the Age of 70 Followed for Breast Cancer: COG-TAB-AGE Feasibility Study
Enrollment Status: Completed
Publish Date: July 02, 2026
Intervention Type: Other
Study Phase: Not Applicable
A European, Multi-centre Phase II Trial of Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck (HNSCC)
A European, Multi-centre Phase II Trial of Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck (HNSCC)
Enrollment Status: Completed
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Atezolizumab, Bevacizumab
Study Phase: Phase 2
Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy
Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy
Enrollment Status: Completed
Publish Date: March 18, 2026
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
Evaluation of the Impact of Emotional Skills of Young Women (≤ 45 Years), With Non-metastatic Breast Cancer, and Their Partner on Adjustment to Cancer
Evaluation of the Impact of Emotional Skills of Young Women (≤ 45 Years), With Non-metastatic Breast Cancer, and Their Partner on Adjustment to Cancer
Enrollment Status: Completed
Publish Date: March 18, 2026
Intervention Type: Behavioral, Other
Study Phase: Not Applicable
Phase III Randomized Clinical Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer Considering Two Different Settings: Primary Debulking Surgery (PDS) and Interval Debulking Surgery (IDS)
Phase III Randomized Clinical Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer Considering Two Different Settings: Primary Debulking Surgery (PDS) and Interval Debulking Surgery (IDS)
Enrollment Status: Active_not_recruiting
Publish Date: March 16, 2026
Intervention Type: Drug
Study Drug: HIPEC
Study Phase: Phase 3
Impact of Adjuvant Chemotherapy on the Quality of Life of Patients Treated for Stage II / III Endometrial Cancer
Impact of Adjuvant Chemotherapy on the Quality of Life of Patients Treated for Stage II / III Endometrial Cancer
Enrollment Status: Completed
Publish Date: December 18, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02
A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02
Enrollment Status: Completed
Publish Date: June 01, 2021
Intervention Type: Drug
Study Drug: Afatinib
Study Phase: Phase 3
Phase II Multicenter Study to Determine the Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas
Phase II Multicenter Study to Determine the Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas
Enrollment Status: Completed
Publish Date: January 31, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

48 Total Publications

Clinical outcomes and prognostic factors in advanced high-grade platinum-resistant ovarian carcinoma: evidence from the ESME real-world cancer database.
Clinical outcomes and prognostic factors in advanced high-grade platinum-resistant ovarian carcinoma: evidence from the ESME real-world cancer database.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: May 15, 2026

Frequently Asked Questions about Cecile Guillemet

Is Cecile Guillemet a top-rated expert for Adult Soft Tissue Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Cecile Guillemet is classified as an Distinguished expert for Adult Soft Tissue Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Cecile Guillemet participate in research or clinical trials?

Yes. Cecile Guillemet has published 48 articles and abstracts on conditions like Adult Soft Tissue Sarcoma. You can view a list of Cecile Guillemet's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Guillemet's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile